1. Home
  2. OPHC vs INDP Comparison

OPHC vs INDP Comparison

Compare OPHC & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OptimumBank Holdings Inc.

OPHC

OptimumBank Holdings Inc.

HOLD

Current Price

$9.15

Market Cap

110.1M

Sector

Finance

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$3.21

Market Cap

125.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPHC
INDP
Founded
2000
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.1M
125.2M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
OPHC
INDP
Price
$9.15
$3.21
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.50
N/A
AVG Volume (30 Days)
103.7K
1.4M
Earning Date
04-24-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.48
N/A
Revenue
N/A
N/A
Revenue This Year
$17,095.98
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$0.92
52 Week High
$10.68
$8.57

Technical Indicators

Market Signals
Indicator
OPHC
INDP
Relative Strength Index (RSI) 55.61 63.84
Support Level $8.57 $2.41
Resistance Level $9.29 $3.75
Average True Range (ATR) 0.37 0.44
MACD -0.05 0.21
Stochastic Oscillator 68.56 70.92

Price Performance

Historical Comparison
OPHC
INDP

About OPHC OptimumBank Holdings Inc.

OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: